Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis

NCT06003283 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

134

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Rituximab

Sponsor

Universitaire Ziekenhuizen KU Leuven

Collaborators

[object Object]